Selecta Biosciences, Inc. (SELB) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

And welcome to the Selecta Bio second quarter 2022 earnings release conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touch tone phone. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Kevin Tan, Chief Financial Officer of Selecta Bio. Please go ahead. Thank you and good morning. Welcome to our second quarter 2022 financial results and corporate update conference call. Press relief reporting our financial results is available in the investors and media section of Selecta's website, worldwidewebselectedbio.com, and our quarterly report on Form 10-Q for the quarter ended June 30th, 2022, which we intend to file in the coming days with the Securities and Exchange Commission, or SEC. Joining me today are Carson Bruhn, President and Chief Executive Officer, Peter Traber, Chief Medical Officer, and Kei Kishimoto, Chief Scientific Officer. During today's call, we will be making certain forward-looking statements, including without limitation, statements about the potential safety efficacy, regulatory and clinical progress of our product candidates, our financial projections, and our future expectations, plans, partnerships, and prospects. These statements are subject to various risks that are described in the filings made with the SEC, including our most recent annual report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, August 4th, 2022, and selected as...